<DOC>
	<DOCNO>NCT00612040</DOCNO>
	<brief_summary>This trial conduct Europe , Oceania United States America ( USA ) . The aim trial compare two NN1250 ( insulin degludec ) formulation insulin glargine , combination insulin aspart subject type 1 diabetes .</brief_summary>
	<brief_title>Comparison Two NN1250 Formulations Versus Insulin Glargine , All Combination With Insulin Aspart Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes least one year HbA1c 711 % ( inclusive ) Treated insulin least six month regimen Any systemic treatment product Investigator 's opinion could interfere glucose lipid metabolism ( eg systemic corticosteroid ) 3 month prior randomisation Subject clinically significant , active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , genitourinary , haematological system , opinion Investigator , may confound result trial pose additional risk administer trial product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>